Dhizhayo Wart Remover

Description

No description information is available for the specified drug.

Uses and Indications

This drug is indicated for the removal of common warts, characterized by a rough, cauliflower-like appearance.

There are no teratogenic or nonteratogenic effects associated with this drug.

Dosage and Administration

Healthcare professionals are advised to instruct patients to wash the affected area thoroughly. Soaking the area in warm water for approximately 5 minutes may facilitate this process. After cleansing, the area should be dried completely.

A small amount of the medication should then be applied directly to cover each wart, ensuring that it is allowed to dry. This application should be repeated twice daily as necessary, with treatment continuing for a maximum duration of 12 weeks.

Contraindications

Use of this product is contraindicated in the following situations:

Application on irritated or infected skin, or on areas exhibiting redness, is prohibited due to the potential for exacerbating the condition.

Patients with diabetes or poor blood circulation should not use this product, as it may pose additional risks related to skin integrity and healing.

The product should not be applied to birthmarks, warts with hair growth, or moles, as these conditions may lead to adverse reactions or complications.

Warnings and Precautions

For external use only; contact with the eyes must be avoided. In the event that the product comes into contact with the eyes, it is imperative to rinse thoroughly with water for a minimum of 15 minutes. Additionally, inhalation of vapors should be strictly avoided to prevent respiratory irritation.

In cases of accidental ingestion, immediate medical assistance should be sought, or the local Poison Control Center should be contacted without delay.

If discomfort persists after use, it is essential to discontinue use of the product and consult a healthcare professional for further evaluation and guidance.

Side Effects

Patients using this product should be aware that it is intended for external use only. Care should be taken to avoid contact with the eyes; in the event of accidental exposure, it is recommended to rinse the eyes with water for 15 minutes. Additionally, patients should avoid inhaling vapors associated with the product.

In the case of persistent discomfort, patients are advised to discontinue use and consult a healthcare professional. This precaution is important to ensure safety and address any potential adverse reactions that may arise during use.

Drug Interactions

There are currently no documented drug interactions associated with this medication. Additionally, there is no information available regarding interactions with laboratory tests. As such, no specific recommendations for dosage adjustments or monitoring are warranted at this time.

Packaging & NDC

Below are the non-prescription pack sizes of Dhizhayo Wart Remover (salicylic acid 17% wart remover). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients should be advised to keep this medication out of reach of children. In the event of accidental ingestion, immediate medical assistance should be sought, or the local Poison Control Center should be contacted.

Geriatric Use

Elderly patients may not have specific information regarding the use of this medication, including dosage adjustments, safety concerns, or special precautions. Therefore, healthcare providers should exercise caution when prescribing this medication to geriatric patients. It is advisable to monitor these patients closely for any potential adverse effects or changes in efficacy, given the lack of targeted data for this population.

Pregnancy

Pregnant patients and those who are breastfeeding should consult a healthcare professional prior to using this medication. It is essential to evaluate the potential risks and benefits in these populations to ensure the safety of both the mother and the fetus or infant.

Lactation

Lactating mothers are advised to consult a health professional prior to using this medication. There is currently no available data regarding the excretion of this medication in human breast milk or its effects on breastfed infants. Therefore, caution is recommended when administering this medication to lactating individuals.

Renal Impairment

Patients with renal impairment have not been specifically addressed in the available prescribing information. There are no dosage adjustments, special monitoring requirements, or safety considerations outlined for individuals with reduced kidney function. Healthcare professionals should exercise caution and consider the lack of data when prescribing to this patient population.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to this medication. Consequently, there are no established dosage adjustments, special monitoring requirements, or precautions for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the prescribing information.

Overdosage

There is currently no specific information available regarding overdosage for this medication. In the absence of documented overdosage data, healthcare professionals are advised to exercise caution and monitor patients closely for any unusual symptoms or adverse effects that may arise following administration.

In the event of suspected overdosage, it is recommended that healthcare providers initiate supportive care and symptomatic treatment as necessary. Continuous monitoring of vital signs and clinical status is essential to ensure patient safety.

Healthcare professionals should also consider consulting a poison control center or a medical toxicologist for guidance on management strategies tailored to the individual patient's needs.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data limits the assessment of potential risks associated with the compound in these areas.

Postmarketing Experience

No postmarketing experience details are available in the insert.

Patient Counseling

Healthcare providers should advise patients to seek immediate medical help or contact a Poison Control Center if the product is swallowed. It is important to inform patients that the product should not be used on irritated or infected skin, or on areas that are reddened. Additionally, patients with diabetes or poor blood circulation should be cautioned against using the product. The use of the product is also contraindicated on birthmarks, warts with hair growth, or moles.

Patients should be instructed to stop using the product and consult a doctor if discomfort persists. Furthermore, it is essential to recommend that pregnant or breastfeeding patients consult a health professional before using the product to ensure safety for both themselves and their child.

Storage and Handling

The product is supplied in a tube that must be kept tightly closed when not in use to maintain its integrity. It should be stored at room temperature, away from direct light to protect it from degradation. Once opened, the product should be discarded to ensure safety and efficacy.

Additional Clinical Information

The product is administered topically, with a recommendation to apply a small amount to cover each wart and allow it to dry. This application should be repeated twice daily as needed, for a duration of up to 12 weeks. Clinicians should advise patients who are pregnant or breastfeeding to consult a health professional prior to use. No additional information is available regarding laboratory tests, abuse potential, or postmarketing experience.

Drug Information (PDF)

This file contains official product information for Dhizhayo Wart Remover, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)